The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Open accessAbstract
Objective: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods: Amyloid‐β 1 to 42 peptide (Aβ 1–42), total tau (t‐tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy‐confirmed AD cases and 52 age‐matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t‐tau and Aβ 1–42 in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy‐confirmed CSF data. Results: CSF Aβ 1–42 was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for Aβ 1–42, t‐tau, and APO ε 4 allele count provided the best assessment delineation of mild AD. An AD‐like baseline CSF profile for t‐tau/Aβ 1–42 was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. Interpretation: The CSF biomarker signature of AD defined by Aβ 1–42 and t‐tau in the autopsy‐confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
Cited by
Sorted by citations
Items 801–900 of 1,012
Biomarkers for Predicting Cognitive Decline in those with Normal Cognition
Steenland, K., Initiative, A. D. N., Zhao, L., Goldstein, F. C., Cellar, J. S., & Lah, J. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-2014-131343 · Cited by 44
Self-citationNeuroimaging predictors of brain amyloidosis in mild cognitive impairment
Tosun, D., Joshi, S. C., & Weiner, M. W. (2013) · Annals of Neurology · doi:10.1002/ana.23921 · Cited by 43
Lee, E., Hongtu Zhu, B., Kong, D., Wang, Y., Giovanello, K. S., Ibrahim, J. G., & Initiative, A. D. N. (2015) · The Annals of Applied Statistics · doi:10.1214/15-aoas879 · Cited by 42
Self-citationAPOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease
Sun, X., Dong, C., Levin, B. E., Crocco, E., Loewenstein, D., Zetterberg, H., Blennow, K., Wright, C. B., & Initiative, A. D. N. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.05.003 · Cited by 44
Self-citationMeyer, P., Savard, M., Poirier, J., Labonté, A., Rosa‐Neto, P., Weitz, T. M., Town, T., Breitner, J. C. S., & Initiative, A. D. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170887 · Cited by 44
Self-citationInitiative, A. D. N., Petrone, P., Casamitjana, A., Falcón, C., Artigues, M., Operto, G., Cacciaglia, R., Molinuevo, J. L., Vilaplana, V., & Gispert, J. D. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0526-8 · Cited by 42
Self-citationTelomere length associations with cognition depend on Alzheimer's disease biomarkers
Mahoney, E. R., Dumitrescu, L. C., Seto, M., Nudelman, K. N. H., Buckley, R. F., Gifford, K. A., Saykin, A. J., Jefferson, A. L., Hohman, T. J., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.003 · Cited by 46
Self-citationLongitudinal Speech Biomarkers for Automated Alzheimer's Detection
Laguarta, J., Hueto, F., Rajasekaran, P., Sarma, S. E., & Subirana, B. (2021) · Frontiers in Computer Science · doi:10.3389/fcomp.2021.624694 · Cited by 50
Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
Vromen, E. M., de Boer, S. C. M., Teunissen, C. E., Rozemüller, A. J. M., Sieben, A., Bjerke, M., Initiative, A. D. N., Visser, P. J., Bouwman, F. H., Engelborghs, S., et al. (2022) · Brain · doi:10.1093/brain/awac158 · Cited by 45
Self-citationBiomarkers of Parkinson's disease and Dementia with Lewy bodies
Henchcliffe, C., Dodel, R. C., & Beal, M. F. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.002 · Cited by 42
Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers
Berger, M., Browndyke, J. N., Cooter, M. L., Nobuhara, C. K., Reese, M. A., Acker, L., Bullock, W. M., Colin, B. J., Devinney, M. J., Moretti, E. W., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51499 · Cited by 41
Self-citationSchmand, B. A., Initiative, A. D. N., Eikelenboom, P., & van Gool, W. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111703 · Cited by 41
Self-citationLi, Q. S., Parrado, A., Samtani, M. N., Narayan, V. A., & Initiative, A. D. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134000 · Cited by 41
Self-citationCSF and Brain Structural Imaging Markers of the Alzheimer's Pathological Cascade
Yang, X., Tan, M., & Qiu, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047406 · Cited by 41
The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO
Zhang, D., Fa, H., Zhou, J., Li, S., Diao, X.-W., & Yin, W. H. (2014) · Clinical Radiology · doi:10.1016/j.crad.2014.09.019 · Cited by 43
Bros, P., Delatour, V., Vialaret, J., Lalère, B., Barthélemy, N. R., Gabelle, A., Lehmann, S., & Hirtz, C. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1048 · Cited by 41
Perneczky, R., Alexopoulos, P., & Initiative, A. D. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.006 · Cited by 41
Self-citationA Candidate Plasma Protein Classifier to Identify Alzheimer's Disease
Zhao, X., Lejnine, S., Spond, J., Zhang, C., Ramaraj, T. C., Holder, D., Dai, H. A., WEINER, R. S., & Laterza, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141149 · Cited by 43
Cerebrospinal fluid biomarkers for Alzheimerʼs disease
Zetterberg, H. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000179 · Cited by 42
Luo, X., Li, K., Zeng, Q., Huang, P., Jiaerken, Y., Wang, S., Shen, Z., Xu, X., Xu, J., Wang, C., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00904 · Cited by 40
Hu, X., Pickering, E. H., Hall, S. K., Naik, S. U., Liu, Y., Soares, H. D., Katz, E., Paciga, S. A., Liu, W., Aisen, P. S. S., et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.50 · Cited by 40
Self-citationLin, F. V., Wang, X., Wu, R., Rebok, G. W., Chapman, B. P., & Initiative, T. A. D. N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161278 · Cited by 41
Schelle, J., Häsler, L. M., Göpfert, J. C., Joos, T. O., Vanderstichele, H., Stoops, E., Mandelkow, E., Neumann, U., Shimshek, D. R., Staufenbiel, M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.005 · Cited by 40
Self-citationWhite matter lesions may be an early marker for age-related cognitive decline
Morrison, C., Dadar, M., Villeneuve, S., Collins, D. L., & Initiative, A. D. N. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103096 · Cited by 40
Association of neurofilament light chain with renal function: mechanisms and clinical implications
Tang, R., Panizzon, M. S., Elman, J. A., Gillespie, N. A., Hauger, R. L., Rissman, R. A., Lyons, M. J., Neale, M. C., Reynolds, C. A., Franz, C. E., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01134-0 · Cited by 40
Self-citationBiomarkers: Role and Scope in Neurological Disorders
Sharma, V., Singh, T. G., Mehta, V., & Mannan, A. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03873-4 · Cited by 46
Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach
Wang, X., Ye, T., Zhou, W., Zhang, J., & Initiative, A. D. N. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01205-w · Cited by 44
Self-citationKokkinou, M., Beishon, L., Smailagic, N., Noel-Storr, A. H., Hyde, C., Ukoumunne, O. C., Worrall, R., Hayen, A., Desai, M., Ashok, A. H., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010945.pub2 · Cited by 43
Kitaguchi, N., Hasegawa, M., Ito, S., Kawaguchi, K., Hiki, Y., Nakai, S., Suzuki, N., Shimano, Y., Ishida, O., Kushimoto, H., et al. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1431-3 · Cited by 40
Sierra, A., Balasa, M., Olives, J., Antonell, A., Iranzo, Á., Castellvı́, M., Bosch, B., Grau‐Rivera, O., Fernández‐Villullas, G., Rami, L., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000439258 · Cited by 42
Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age
Pletniková, O., Rudow, G. L., Hyde, T. M., Kleinman, J. E., Ali, S. Z., Bharadwaj, R. A., Gangadeen, S., Crain, B. J., Fowler, D. R., Rubio, A. I., et al. (2015) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000071 · Cited by 40
Chiasserini, D., Biscetti, L., Farotti, L., Eusebi, P., Salvadori, N., Lisetti, V., Baschieri, F., Chipi, E., Frattini, G., Stoops, E., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160298 · Cited by 40
Self-citationScott, J. A., Braskie, M. N., Tosun, D., Maillard, P., Thompson, P. M., Weiner, M. W., DeCarli, C. S., & Carmichael, O. T. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.014 · Cited by 41
Prognostic value of amyloid PET scan in normal pressure hydrocephalus
Jang, H., Park, S. B., Kim, Y., Kim, K. W., Lee, J. I., Kim, S. T., Lee, K. H., Kang, E., Choe, Y. S., Seo, S. W., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8650-5 · Cited by 41
Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene
Yao, X., Risacher, S. L., Nho, K., Saykin, A. J., Wang, Z., & Shen, L. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.06.003 · Cited by 40
Recognition Memory Performance as a Cognitive Marker of Prodromal Alzheimer’s Disease
Goldstein, F. C., Loring, D. W., Thomas, T., Saleh, S., & Hajjar, I. M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190468 · Cited by 42
Abe, K., Chiba, Y., Hattori, S., Yoshimi, A., Asami, T., Katsuse, O., Suda, A., & Hishimoto, A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116989 · Cited by 41
Sala, A., Nordberg, A. K., Rodriguez‐Vieitez, E., & Initiative, A. D. N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00950-w · Cited by 43
Self-citationHippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease
Greene, S. J., Killiany, R., & Initiative, T. A. D. N. (2011) · The Anatomical Record · doi:10.1002/ar.21493 · Cited by 40
Xu, W., Han, S., Zhang, C. M., Li, J., Wang, Y., Tan, C., Li, H.-Q., Dong, Q., Mei, C., Tan, L., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb3063 · Cited by 39
Zhang, W., Young, J. I., Gomez, L., Schmidt, M. A., Lukacsovich, D., Varma, A., Chen, X. S., Martin, E. R., & Wang, L. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01216-7 · Cited by 38
Cullen, V., Fredenburg, R. A., Evans, C. L., Conliffe, P. R., & Solomon, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9360-7 · Cited by 40
Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging
Shim, Y. S., & Morris, J. C. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.2.60 · Cited by 41
Yu, P., Initiative, A. D. N., Dean, R. A., Hall, S. D., Qi, Y., Sethuraman, G., Willis, B. A., Siemers, E., Martényi, F., Tauscher, J. T., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120832 · Cited by 42
Self-citationBerlyand, Y., Weintraub, D. A., Xie, S. X., Mellis, I. A., Doshi, J. J., Rick, J. H., McBride, J. D., Davatzikos, C. A., Shaw, L. M. J., Hurtig, H. I., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147319 · Cited by 39
Self-citationProgressive medial temporal lobe atrophy during preclinical Alzheimer's disease
Pettigrew, C. A., Soldan, A., Sloane, K. L., Cai, Q., Wang, J., Wang, M., Moghekar, A., Miller, M. I., & Albert, M. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.08.022 · Cited by 39
Longitudinal validity of PET‐based staging of regional amyloid deposition
Jelistratova, I., Teipel, S. J., & Grothe, M. J. (2020) · Human Brain Mapping · doi:10.1002/hbm.25121 · Cited by 39
Zhang, B., Lin, L., & Wu, S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201274 · Cited by 40
Aging, Senescence, and Human Variation
Crews, D. E., & Ice, G. H. (2012) · Human Biology · doi:10.1002/9781118108062.ch13 · Cited by 39
Tang, W., Huang, Q., Wang, Y., Wang, Z.-Y., & Yao, Y.-Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.015 · Cited by 38
Avelar‐Pereira, B., Belloy, M. E., O'Hara, R. M., Hosseini, S. M. H., & Initiative, A. D. N. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01886-z · Cited by 42
Self-citationFeasibility of an early Alzheimer's disease immunosignature diagnostic test
Restrepo, L., Stafford, P., & Johnston, S. A. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.09.014 · Cited by 38
CSF beta‐amyloid 1–42 – what are we measuring in Alzheimer's disease?
Hu, W. T., Watts, K. D., Shaw, L. M. J., Howell, J. C., Trojanowski, J. Q., Basra, S. S., Glass, J. D., Lah, J. J., & Levey, A. I. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.160 · Cited by 38
Self-citationThe Neuropsychiatric Examination of the Young-Onset Dementias
Ducharme, S., & Dickerson, B. C. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.01.002 · Cited by 39
Amyloid-β and τ biomarkers in Parkinson's disease–dementia
Buongiorno, M., Compta, Y., & Martı́, M. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.06.046 · Cited by 39
McMillan, C. T., & Wolk, D. A. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312690 · Cited by 39
Minhas, S., Khanum, A., Riaz, F., Alvi, A., & Khan, S. A. (2016) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2016.2608998 · Cited by 38
Insulin-like growth factor binding protein-2 interactions with Alzheimer’s disease biomarkers
Initiative, A. D. N., Lane, E., Hohman, T. J., & Jefferson, A. L. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9636-0 · Cited by 38
Self-citationSala, I., Illán‐Gala, I., Alcolea, D. A., Sánchez‐Saudinós, M. B., Salgado, S. A., Morenas‐Rodríguez, E., Subirana, A., Videla, L., Clarimón, J., Carmona‐Iragui, M., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170073 · Cited by 38
Emerging Diagnostic and Therapeutic Strategies for Tauopathies
Coughlin, D. G., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 42
Statistical tests and identifiability conditions for pooling and analyzing multisite datasets
Zhou, H., Singh, V., Johnson, S. C., Wahba, G., Initiative, T. A. D. N., Fleisher, A., Preda, A., Pierce, A., Mintz, A., Lerner, A. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719747115 · Cited by 38
Self-citationHonarpisheh, P., & McCullough, L. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14675 · Cited by 41
Zeng, Q., Luo, X., Li, K., Wang, S., Zhang, R., Hong, H., Huang, P., Jiaerken, Y., Xu, X., Xu, J., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00350 · Cited by 37
Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques
Ezzati, A., Harvey, D. J., Habeck, C. G., Golzar, A., Qureshi, I., Zammit, A. R., Hyun, J., Truelove‐Hill, M., Hall, C. B., Davatzikos, C. A., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191038 · Cited by 37
Self-citationUsefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment
Balasa, M., Sánchez‐Valle, R., Antonell, A., Bosch, B., Olives, J., Rami, L., Castellvı́, M., Molinuevo, J. L., & Lladó, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132195 · Cited by 39
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment
Nosheny, R. L., Insel, P. S., Truran, D., Schuff, N. W., Jack, C. R., Aisen, P. S. S., Shaw, L. M. J., Trojanowski, J. Q., & Weiner, M. W. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.036 · Cited by 39
Self-citationKounnas, M. Z., Lane‐Donovan, C., Nowakowski, D. W., Herz, J., & Comer, W. T. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.09.003 · Cited by 37
Early Prediction of Alzheimer’s Disease Using Null Longitudinal Model-Based Classifiers
Gavidia‐Bovadilla, G., Kanaan-Izquierdo, S., Mataró, M., Perera-Lluna, A., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168011 · Cited by 37
Self-citationPre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
Tijms, B. M., Vermunt, L., Zwan, M. D., van Harten, A. C., van der Flier, W. M., Teunissen, C. E., Scheltens, P., Visser, P. J., & for, A. D. N. I. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.615 · Cited by 38
Initiative, A. D. N., Wei, H., Kong, M., Zhang, C., Guan, L., & Ba, M. (2018) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2018.10.08 · Cited by 37
Self-citationAnsart, M., Epelbaum, S., Gagliardi, G. P., Olivier Colliot, A., Dormont, D., Dubois, B., Hampel, H. J., Durrleman, S., & Initiative, A. D. N. (2019) · Statistical Methods in Medical Research · doi:10.1177/0962280218823036 · Cited by 36
Self-citationATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration
Cousins, K. A. Q., Irwin, D. J., Wolk, D. A., Lee, E. B., Shaw, L. M. J., Trojanowski, J. Q., Re, F. D., Gibbons, G. S., Grossman, M., & Phillips, J. S. (2020) · Brain · doi:10.1093/brain/awaa165 · Cited by 39
Self-citationMohanty, R., Mårtensson, G., Poulakis, K., Muehlboeck, J., Rodriguez‐Vieitez, E., Chiotis, K., Grothe, M. J., Nordberg, A. K., Ferreira, D., Westman, E., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa192 · Cited by 39
Self-citationAssessing mild cognitive impairment using object‐location memory in immersive virtual environments
Castegnaro, A., Howett, D., Li, A., Harding, E. M., Chan, D., Burgess, N., & King, J. A. (2022) · Hippocampus · doi:10.1002/hipo.23458 · Cited by 37
Körtvélyessy, P., Gukasjan, A., Sweeney‐Reed, C. M., Heinze, H., Thurner, L., & Bittner, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150069 · Cited by 37
Ho, L., Fivecoat, H. C., Wang, J., & Pasinetti, G. M. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.09.007 · Cited by 38
Hendrix, S. B. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt127 · Cited by 37
Genome-wide association and interaction studies of CSF T-tau/Aβ42 ratio in ADNI cohort
Li, J., Zhang, Q., Chen, F., Meng, X., Liu, W., Chen, D., Yan, J., Kim, S., Wang, L., Feng, W., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.007 · Cited by 37
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35
Tubi, M. A., Kothapalli, D., Hapenney, M., Feingold, F. W., Mack, W. J., King, K. S., Thompson, P. M., & Braskie, M. N. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.025 · Cited by 38
Plasma phosphorylated tau181 predicts cognitive and functional decline
Tropea, T. F., Waligórska, T., Xie, S. X., Nasrallah, I. M., Cousins, K. A. Q., Trojanowski, J. Q., Grossman, M., Irwin, D. J., Weintraub, D. A., Lee, E. B., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51695 · Cited by 39
Self-citationSong, J., Cho, E., Lee, H., Lee, S., Kim, S., & Kim, J. (2025) · Biosensors · doi:10.3390/bios15020102 · Cited by 38
Pan, C., Korff, A., Galasko, D. R., Ginghină, C., Peskind, E. R., Li, G., Quinn, J. F., Montine, T. J., Cain, K. C., Shi, M. Y., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143099 · Cited by 36
Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up
Li, S., Okonkwo, O. C., Albert, M., & Wang, M. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.7726/ajad.2013.1002 · Cited by 39
Struyfs, H., Molinuevo, J. L., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131085 · Cited by 37
Orellana, C., Ferreira, D., Muehlboeck, J., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Soininen, H. S., Lovestone, S., Simmons, A., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000442443 · Cited by 36
Dicks, E., Vermunt, L., van der Flier, W. M., Visser, P. J., Barkhof, F., Scheltens, P., & Tijms, B. M. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101786 · Cited by 36
Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer’s disease
Wang, L., Gao, T., Cai, T., Li, K., Zheng, P., & Liu, J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134658 · Cited by 35
Cousins, K. A. Q., Phillips, J. S., Irwin, D. J., Lee, E. B., Wolk, D. A., Shaw, L. M. J., Zetterberg, H., Blennow, K., Burke, S., Kinney, N. G., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12233 · Cited by 38
Self-citationImmune-related biomarkers for Parkinson's disease
Abdi, I. Y., Ghanem, S. S., & El‐Agnaf, O. M. A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105771 · Cited by 38
Sex differences in Alzheimer’s disease: plasma MMP-9 and markers of disease severity
Tsiknia, A. A., Sundermann, E. E., Reas, E. T., Edland, S. D., Brewer, J. B., Galasko, D. R., Banks, S. J., & Initiative, A. D. N. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01106-4 · Cited by 39
Self-citationLam, B., Hollingdrake, E., Kennedy, J. L., Black, S. E., & Masellis, M. (2009) · Human Genomics · doi:10.1186/1479-7364-4-2-91 · Cited by 37
The Arc Gene Confers Genetic Susceptibility to Alzheimer’s Disease in Han Chinese
Initiative, A. D. N., Bi, R., Kong, L., Xu, M., Li, G.-D., Zhang, D., Li, T., Fang, Y., Zhang, C., Zhang, B., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0397-6 · Cited by 39
Self-citationMartí‐Juan, G., Lorenzi, M., & Piella, G. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.119892 · Cited by 41
ADNI Biomarker Core: A review of progress since 2004 and future challenges
Shaw, L. M. J., Korecka, M., Lee, E. B., Cousins, K. A. Q., Vanderstichele, H., Schindler, S. E., Tosun, D., DeMarco, M. L., Brylska, M., Wan, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14264 · Cited by 38
Self-citationAlzheimer's disease — Recent biomarker developments in relation to updated diagnostic criteria
Höglund, K., Fourier, A., Perret‐Liaudet, A., Zetterberg, H., Blennow, K., & Portelius, E. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.041 · Cited by 39
Self-citationUsing Biomarkers to Improve Detection of Alzheimer’s Disease
Biagioni, M. C., & Galvin, J. E. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.11 · Cited by 35
Takeda, A., Nakamura, M., Fujii, H., Uematsu, C., Minamino, T., Adlard, P. A., Bush, A. I., & Tamano, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115923 · Cited by 35
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
Insel, P. S., Mattsson, N., Mackin, R. S., Kornak, J., Nosheny, R. L., Tosun, D., Donohue, M., Aisen, P. S. S., Weiner, M. W., & Initiative, A. D. N. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.192 · Cited by 34
Self-citationAmyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
Initiative, A. D. N., Pascoal, T. A., Mathotaarachchi, S. S., Shin, M., Park, A. Y., Mohades, S., Benedet, A. L., Kang, M. S., Massarweh, G., Soucy, J., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3933-3 · Cited by 34
Self-citation
Metadata
- Authors
- Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. ‐., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- University of Pennsylvania (US)
- Fujirebio (Belgium) (BE)
- University of California San Diego (US)
- Mayo Clinic (US)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Eli Lilly (United States) (US)
- Corresponding author
- Shaw, Leslie M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 403-413
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2696350
- OpenAlex
- W2008301592
- Cited by
- 2,065
- References
- 31
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 110 · 2023: 89 · 2022: 114 · 2021: 125 · 2020: 136 · 2019: 141 · 2018: 129 · 2017: 135 · 2016: 121 · 2015: 146 · 2014: 131 · 2013: 130 · 2012: 136
- FWCI
- 85.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, AG 024904, P30AG010124, AG-10124, U19AG010483, U19AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, mild cognitive impairment, conversion to Alzheimer's disease, APOE ε4, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Diagnostic Imaging, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Threonine, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Statistics, Nonparametric, Area Under Curve, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
